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Background-—NADPH Oxidase 5 (Nox5) is a calcium-sensitive superoxide-generating Nox. It is present in lower forms and higher
mammals, but not in rodents. Nox5 is expressed in vascular cells, but the functional significance remains elusive. Given that
contraction is controlled by calcium and reactive oxygen species, both associated with Nox5, we questioned the role of Nox5 in
pro-contractile signaling and vascular function.
Methods and Results-—Transgenic mice expressing human Nox5 in a vascular smooth muscle cell–specific manner (Nox5 mice)
and Rhodnius prolixus, an arthropod model that expresses Nox5 endogenoulsy, were studied. Reactive oxygen species generation
was increased systemically and in the vasculature and heart in Nox5 mice. In Nox5-expressing mice, agonist-induced
vasoconstriction was exaggerated and endothelium-dependent vasorelaxation was impaired. Vascular structural and mechanical
properties were not influenced by Nox5. Vascular contractile responses in Nox5 mice were normalized by N-acetylcysteine and
inhibitors of calcium channels, calmodulin, and endoplasmic reticulum ryanodine receptors, but not by GKT137831 (Nox1/4
inhibitor). At the cellular level, vascular changes in Nox5 mice were associated with increased vascular smooth muscle cell [Ca2+]i,
increased reactive oxygen species and nitrotyrosine levels, and hyperphosphorylation of pro-contractile signaling molecules
MLC20 (myosin light chain 20) and MYPT1 (myosin phosphatase target subunit 1). Blood pressure was similar in wild-type and
Nox5 mice. Nox5 did not amplify angiotensin II effects. In R. prolixus, gastrointestinal smooth muscle contraction was blunted by
Nox5 silencing, but not by VAS2870 (Nox1/2/4 inhibitor).
Conclusions-—Nox5 is a pro-contractile Nox isoform important in redox-sensitive contraction. This involves calcium-calmodulin and
endoplasmic reticulum–regulated mechanisms. Our findings define a novel function for vascular Nox5, linking calcium and reactive
oxygen species to the pro-contractile molecular machinery in vascular smooth muscle cells. ( J Am Heart Assoc. 2018;7:
e009388. DOI: 10.1161/JAHA.118.009388.)
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N oxs (NADPH oxidases) are a family of enzymes thatfunction primarily to produce reactive oxygen species
(ROS) by using molecular oxygen and NADPH as substrates. In
phagocytic cells, ROS play a role in host-defense responses,
and in nonphagocytic cells, ROS control cell differentiation,
proliferation, apoptosis, and senescence.1,2 In the vascular
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system, ROS regulate vasculogenesis, endothelial function,
and vascular tone.3,4 In cardiovascular diseases, such as
hypertension,5 atherosclerosis,6 and pulmonary arterial hyper-
tension,7 Nox-derived ROS generation is increased, leading to
endothelial dysfunction and vascular injury. The mammalian
Nox family comprises 7 isoforms, Nox1 to 5 and dual oxidase
1 and dual oxidase 2, of which Nox1, 2, 4, and 5 have been
identified in human vessels.8,9 Vascular Noxs have different
functions in pathological conditions. Nox1 and Nox2 play a
role in angiogenesis and atherosclerosis,3,6 and Nox4 seems
to be vasoprotective in ischemic and hypoxic conditions,10 but
injurious in diabetes mellitus, where it promotes vascular
fibrosis, diabetic nephropathy, and intravitreal
neovascularization.11 Although Nox5 is expressed in mam-
malian vessels,12–14 there is a paucity of information on its
role and biological significance in the cardiovascular system.
Unlike the other vascular Nox isoforms, Nox5 gene is
absent in rodents; it generates ROS from a single gene
product and does not require classical NADPH oxidase
subunits (p22phox, p47phox, and p67phox) for its
activation.15 Nox5 is the only Nox isoform that has been
crystalized.16 Unique to Nox5 is its long N-terminal extension
that contains 4 calcium (Ca2+)-binding EF hands, which
undergoes conformational change upon Ca2+ binding.17,18
Increased intracellular free Ca2+ concentration ([Ca2+]i) is
essential for the activity of Nox5,18–20 as evidenced in cell-
culture studies where ROS are not synthesized in Ca2+-free
buffer or from cells with truncation of the N-terminal region of
Nox5.21 This is of particular significance in vascular smooth
muscle cells (VSMCs), given that increased [Ca2+]i is the
major trigger for vascular contraction.22,23 Nox5 is expressed
in all vascular cell types, including endothelial cells, VSMCs,
and perivascular adventitial fibroblast,12,14,24 and plays a role
in angiotensin II (Ang II)- and endothelin-1 (ET-1)-mediated
redox signaling.25 Nox5 expression is increased in human
atherosclerotic and aneurysm lesions26,27 and in kidneys from
diabetic patients.28 We demonstrated that mice expressing
human Nox5 in a podocyte-specific manner exhibit podocyte
injury and renal dysfunction,28 and that human Nox5 expres-
sion in mesangial cells causes renal fibrosis, nephropathy, and
exacerbated atherosclerosis in diabetic mice.29 Findings from
recent genome wide-association studies of 475 000 individ-
uals identified Nox5 as a candidate blood pressure–associ-
ated gene.30 Together, these data suggest an important
(patho)physiological role for Nox5 in the cardiovascular
system. However, the exact function of VSMC Nox5 and its
biological significance in the vascular system are unknown.
Using a multidisciplinary approach including transgenic
Nox5 mice with selective expression of Nox5 in smooth
muscle cells, cultured VSMCs from Nox5-expressing mice,
and an arthropod model that endogenously expresses Nox5,31
we identify a novel role for Nox5 as an important pro-
contractile NADPH oxidase isoform that regulates vascular
contraction and reactivity. We also elucidate some molecular
mechanisms underlying Nox5 vascular effects. Nox5 dysreg-
ulation may contribute to vascular injury and dysfunction in
pathological conditions.
Methods
Mice Expressing Human Nox5 in VSMCs
Generation of Nox5 transgenic mice was approved by the
Animal Ethics Committee of the Ottawa Hospital Research
Institute, University of Ottawa (Ottawa, Ontario, Canada) and
carried out according to the recommendations of the Canadian
Council for Animal Care. NOX5b cDNA was PCR amplified from
pDONRNox5b plasmid. Purified PCR NOX5b gene-coding
region was ligated into the Tet-responsive promoter, Pbi-1. A
3.7-kb TetO/NOX5b fragment was excised and the resulting
band gel-purified and provided to the University of Ottawa Core
Transgenic Facility for pronuclear injection into fertilized FVB/N
oocytes. Subsequent pBI-NOX5b founders on a pure FVB/N
background were identified by PCR genotyping. To generate
VSMC-specific knockout animals, pBI-Nox5 animals were
crossed with the SM22-tTA-FVB/N mouse strain to produce
Nox5+/SM22+ and control transgenic mice (SM22+, Nox5+).
In additional studies, adult (20 weeks) WT, SM22+, Nox5+,
and Nox5+/SM22+ mice were infused with Ang II (600 ng/
kg/day) for 4 weeks by osmotic minipumps. At the end of
treatment, tissues were snap-frozen or fixed in formalin for
Clinical Perspective
What Is New?
• We define a biologically important role for NADPH Oxidase 5
(Nox5) as a regulator of vascular contraction.
• Molecular mechanisms whereby Nox5 regulates contraction
involve redox-sensitive processes that influence calcium
channels, calcium mobilization, and pro-contractile
signaling.
• Nox5 is a point of cross-talk between vascular calcium and
redox signaling.
• Vascular Nox5 activation also influences cardiac fibrosis.
What Are the Clinical Implications?
• We identify Nox5 as a key regulator of vascular contraction
and cardiac fibrosis.
• Dysregulation of Nox5 may be associated with oxidative
stress and amplified calcium signaling, leading to vascular
hypercontractility and dysfunction in cardiovascular
diseases.
• Modulating Nox5 may have therapeutic potential by target-
ing both redox and calcium signalling pathways.
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analysis. Animal experiments were performed in accord with
the United Kingdom Animals Scientific Procedures Act 1986
and ARRIVE (Animal Research: Reporting of In Vivo Experi-
ments) Guidelines32 and approved by the Home Office under
Project Licence No. 7009021.
Measurement of Blood Pressure
Systolic blood pressure was assessed by tail-cuff plethys-
mography.33
Plasma Biochemistry and Plasma Lipid
Peroxidation Products
Plasma biochemistry was determined by an automated
analyzer. Plasma lipid peroxidation (malondialdehyde) was
determined by quantifying thiobarbituric acid-reactive sub-
stances by ELISA.
Myography to Assess Vascular Function and
Structure
Vascular function was assessed in resistance arteries by wire
myography as we previously described.34 Endothelium-depen-
dent relaxation was assessed in all vessels by concentration-
responses to acetylcholine (Ach) where vessels were precon-
tracted with U46619 (thromboxane A2 analogue). Thereafter,
endothelium-independent relaxation was assessed by concen-
tration responses to sodium nitroprusside and contractile
responsesmediated by U46619 evaluated in endothelium-intact
arteries. At the end of relaxation and contraction curves, ET-1
induced contraction was assessed. Maximal contraction to KCl
was also evaluated before and after addition of pharmacological
inhibitors. In some experiments, arteries were preincubated with
N-acetylcysteine (ROS scavenger), GKT137831 (Nox1/Nox4
inhibitor), diltiazem (Ca2+ channels blocker), calmidazolium
(calmodulin inhibitor), and dantrolene. Dantrolene is considered
a potent receptor antagonist of the ryanodine receptor Ca2+
channel in the endoplasmic reticulum (ER), which decreases
[Ca2+]i. Studies have demonstrated that dantrolene acts directly
on the ryanodine receptor to reduce channel activation by
calmodulin and decreases Ca2+ sensitivity of channel activation.
Vascular structure and mechanical properties were
assessed in resistance arteries prepared as pressurized
systems on a pressure myograph as we previously described.34
Cardiac Histology and Fibrosis Staining
For histochemical analysis, heart sections were stained with
picrosirius red (0.1% w/v). Total collagen content (%) was
measured in whole tissue under polarized light. To assess
cardiomyocyte area, hematoxylin and eosin staining of heart
sections was performed. Data were quantified by digital image
analysis software (ImageJ; NIH, Bethesda, MD).
Mouse VSMC Culture
VSMCs from adult male WT and Nox5+SM22+ mice were
studied.35 Low-passage cells (4–7) were used. VSMCs were
stimulated with U46619. In some experiments, cells were
preincubated with pharmacological modulators.
Immunofluorescence
Nox5 immunofluorescence was performed in human arteries
obtained from normotensive and hypertensive subjects and in
aortas isolated fromWT, SM22+, Nox5+, andNox5+SM22+mice.
Lucigenin-Enhanced Chemiluminescence Assay
Vascular ROS generation was measured by a luminescence
assay with lucigenin as the electron acceptor and NADPH as
the substrate.
Measurement of Nitrotyrosine and H2O2 Levels
Nitrotyrosine, a measure of peroxynitrite (ONOO) formation,
was assessed in aortic tissue from WT, Nox5+SM22+, SM22+,
and Nox5+ mice by ELISA. H2O2 was assessed in cardiac
tissue from WT, Nox5+SM22+, SM22+, and Nox5+ by Amplex
Red (Life Technologies).
Measurement of Superoxide Anion in Cardiac
Tissue
Superoxide levels in hearts from WT, Nox5+SM22+, SM22+,
and Nox5+ was measured by high-performance liquid chro-
matography.
Western Blotting
Total protein was extracted from mouse VSMCs and from
mesenteric arteries from WT, SM22+, Nox5+, and
Nox5+SM22+ mice. Antibodies were as follows: MYPT1
(myosin phosphatase target subunit 1; Thr696); p-MLC20
(myosin light chain 20; Thr19/Ser 19); Nox1; Nox2; Nox4; and
Nox5. Antibodies to b-actin or GAPDH were used as
housekeeping controls. After incubation with secondary
fluorescence-coupled antibodies (LI-COR Biosciences, Lincoln,
NE), signals were visualized by an infrared laser scanner.
Real-Time PCR
Total RNA was isolated from cardiac samples from WT,
SM22+, Nox5+, and Nox5+SM22+ mice. Real-time PCR was
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performed with specific mouse primers for Nox2 and
Nox4. Data are shown as the fold change in expression of
the target gene relative to the internal control gene
GAPDH.36
Measurement of Intracellular Free Ca2+
Concentration ([Ca2+]i) in VSMCs
[Ca2+]i was measured in VSMCs from WT and Nox5
+/SM22+
mice using the fluorescent Ca2+ indicator, Cal-520 ace-
toxymethyl ester (Cal-520/AM).
Nox5-Expressing Arthropod Model: Rhodnius
prolixus
Rhodnius prolixus was studied as an arthropod model that
expresses Nox5 endogenously. Insects were fed with rabbit
blood as a stimulus for gut contraction.
siRNA Downregulation of Nox5 in R. prolixus
A 457-bp fragment from the Nox5 gene was amplified from
reverse-transcribed RNAs extracted from R. prolixus midguts
using the primer pairs NOX5Ds1. For gene-silencing experi-
ments, adult R. prolixus were injected with dsRNA. Six days
after dsRNA injection, insects were fed.
RNA Extraction, PCR, and qPCR: R. prolixus
Total RNA was extracted from anterior midguts using TRIzol
and cDNA was synthesized. cDNA from anterior midguts were
PCR-amplified using the PCR master mix, and the same
primers were used for qPCR. The R. prolixus EF-1 S rRNA gene
was used as an endogenous control.
VAS2870 Injection in R. prolixus
In some experiments, R. prolixus were injected with VAS2870
to inhibit Nox 1, 2, and 4 six days before feeding.
Images and Video Acquisition of Gut Contractions
in Nox5-Silenced R. prolixus
Nox5-siRNA–injected and VAS2870-treated insects were
studied 7 days after a blood meal. Peristaltic contractions
of the anterior midguts were recorded for 2 minutes by video
fluorescence microscopy.
Statistical Analysis
Data are presented as meanSEM. Statistical comparisons
were made with 1-way ANOVA followed by Dunnet’s post-hoc
or 2-tailed Student t test, when appropriate. P<0.05 was
considered statistically significant.
Data Availability
The data that support the findings of this study are available
from the corresponding author upon reasonable request.
Additional methods can be found in Data S1.
Results
Phenotypic Characterization of Nox5 Mice
The mouse genome lacks Nox5 and, accordingly, to study the
biological in vivo significance of vascular Nox5, we created
humanized transgenic mice that selectively express Nox5 in
smooth muscle cells (Nox5+SM22+). Nox5 expression,
assessed by immunofluorescence, was observed only in
Nox5+SM22+ mice and not in any of the control groups (WT,
SM22+, and Nox5+), confirming the selective Nox5 expression
in the experimental transgenic mice (Figure 1A). Systemic
oxidative stress, measured by plasma levels of lipid peroxi-
dation (plasma malondialdehyde levels), was already
increased in basal conditions in Nox5+SM22 mice (Figure 1B)
and was not further enhanced by Ang II infusion.
Ang II infusion for 4 weeks increased systolic blood
pressure in all groups, without differences between control
and Nox5+SM22+ mice (Figure 1C). Body weight and plasma
biochemistry were not significantly different between groups,
although Ang II increased plasma phosphate levels in WT,
SM22+, and Nox5+SM22+ mice (Table S1). Causes for the
hyperphosphatemia are unclear.
Cardiac superoxide anion (Figure 2A), H2O2 (Figure S1A),
and thiobarbituric acid-reactive substances levels (Figure S1B)
were increased in Nox5+SM22+. Ang II increased superoxide,
H2O2, and TBARS levels only in wild-type (WT) mice. Heart
weight was only increased in control mice treated with Ang II
(Figure 2B). Collagen deposition was increased in hearts from
Nox5+SM22+ mice (Figure 2C and 2D). Ang II increased
collagen deposition in cardiac tissue from WT, mice. Histo-
logical analysis demonstrated that cardiomyocyte area was
increased in cardiac tissue from Nox5+SM22+ mice, to a
similar extent to that in Ang II–infused WT mice (Figure 2E).
Vascular Function in Nox5 Mice
Concentration-response curves to the thromboxane A2
analogue, U46619 (contraction), Ach (endothelial-dependent
relaxation), and sodium nitroprusside (endothelial-indepen-
dent relaxation) were performed in all groups to assess
whether expression of Nox5 in VSMCs influences vascular
function. Vascular contraction induced by U46619 was
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increased in Nox5+SM22+ mice compared with all control
groups (WT, Nox5+, and SM22+; Figure 3A). In Ang II–
infused mice, contractile responses were significantly
enhanced in WT and Nox5+SM22+ mice (Figure 3B). There
were no significant differences in contractile responses
between the control groups (WT, Nox5+, and SM22+) in
basal conditions or in mice treated with Ang II (Figure S2).
The importance of ROS was observed by exposure of
isolated arteries to N-acetylcysteine, an ROS scavenger,
that significantly attenuated U46619-induced contractile
responses in Nox5+SM22+ mice, with only a modest effect
in WT mice (Figure 3C). GKT137831, a Nox1/4 inhibitor,
did not significantly alter contractile responses in WT or
Nox5+SM22+ mice (Figure 3D). In previous studies, we
showed that activation of the Ca2+/calmodulin pathway is
important for Nox5-dependent effects in VSMCs. Here, we
found that contractile responses in WT and Nox5+SM22+
groups were significantly reduced in vessels exposed to the
calmodulin inhibitor, calmidazolium (Figure 3E). Dantrolene,
which inhibits ryanodine receptors and prevents Ca2+
release from the ER, attenuated contraction in Nox5+/
SM22+ mice without effect in WT mice (Figure 3F).
Increased vascular contraction in Nox5+SM22+ mice was
not agonist specific, but appears to be a generalized
phenomenon, given that maximal responses to KCl and ET-
1 were also exaggerated in Nox5-expressing mice com-
pared with control groups (Figure 4). Contractile responses
to KCl and ET-1 were significantly reduced in Nox5+SM22+
vessels exposed to diltiazem, calmidozilium, and N-
acetylcysteine (Figure 4B through 4F). GKT137831 did
not reduce KCl- or ET-1–induced contraction (Figure 4C
through 4E). Associated with exaggerated contraction, Ach-
induced vasorelaxation (endothelium-dependent relaxation)
was significantly reduced in Nox5+SM22+ mice (Figure 5A).
In Ang II–infused WT and Nox5+SM22+ mice, Ach-mediated
vasorelaxation was significantly reduced, with maximal
dilatory responses of only 10% to 20% (Figure 5B). Ach-
mediated responses were not different between respective
WT, Nox5+, and SM22+ control groups (Figure 5C). SNP-
induced vasorelaxation was similar in all groups and was
unaffected by Nox5 expression or by Ang II infusion
(Figure S3A through S3C).
Vascular Structure and Mechanical Properties in
Nox5+SM22+ Mice
Small mesenteric arteries were also studied as pressurized
systems to assess vascular structure and mechanical
properties. In basal conditions, there were no structural
differences between any groups as assessed by measuring
cross-sectional area (Figure 6A) and wall-to-lumen ratio
(Figure S4A). Cross-sectional area was increased in all Ang
II–infused groups (Figure 6B and 6C), with modest effect in
Nox5-expressing mice compared with WT mice. In Ang II–
infused mice, wall-to-lumen ratio was increased in
Nox5+SM22+ mice compared with WT and vehicle-treated
Nox5+/SM22+ counterparts (Figure S4C and S4D). Vascular
stiffness and distensibility, assessed by stress/strain rela-
tionships, were not significantly different between any groups
(Figure S5).
Figure 1. Phenotypic characterization of Nox5+SM22+
mice. (A) Immunolocalization of Nox5 (green fluorescence)
in WT, SM22+, Nox5+, and Nox5+/SM22+ mice. Blue fluores-
cence indicates nucleus (DAPI). B, Plasma TBARS levels in WT,
SM22+, Nox5+, and Nox5+/SM22+ mice. C, Systolic blood
pressure assessed by plethysmography for 4 weeks in WT,
SM22+, Nox5+, and Nox5+SM22+ mice treated or not with
Ang II (600 ng/kg/day). Results are meanSEM of 5 to 8
mice/group. *P<0.05 vs control WT group or untreated group
(BP); **P<0.05 vs nontreated counterpart (TBARS). Ang II
indicates angiotensin II; BP, blood pressure; DAPI, 40,6-
diamidino-2-phenylindole; Nox5, NADPH Oxidase 5; TBARS,
thiobarbituric acid reactive substances; WT, wild-type.
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Molecular Mechanisms Associated With Vascular
Dysfunction in Nox5 Mice
Nox5 produces O2 that interacts with nitric oxide to form
ONOO, which binds to tyrosine residues of proteins to form
nitrotyrosine. As shown in Figure 7A, vascular nitrotyrosine
levels were significantly increased in vessels fromNox5+SM22+
mice. To better evaluate molecular mechanisms contributing to
hypercontractility in Nox5+SM22+ mice, VSMCs cultured from
mesenteric arteries from WT and Nox5+SM22+ mice were
studied. Nox5+SM22+ VSMCs exhibited increased NADPH-
induced ROS production (Figure 7B), effects that were atten-
uated by verapamil, calmidazolium, and dantrolene (Figure 7C).
Stimulation of WT and Nox5+/SM22+ VSMCs with the
vasoconstrictor, U46619, induced a rapid increase in ROS
production (within 5–15 minutes; Figure 7D and 7E). U46619-
induced ROS production was inhibited in Nox5+SM22+ VSMCs
pretreated with verapamil and dantrolene (Figure 7F).
Keymolecular processes involved in vascular contraction are
increased [Ca2+]i and phosphorylation of MYPT1 and MLC20,
Figure 2. Cardiac phenotypic characterization of Nox5+SM22+ mice. A, Superoxide anion levels assessed
by HPLC in heart tissue from WT (open bars) and SM22+Nox5+ (closed bars) mice, before and after Ang II
treatment. B, Heart weight in WT, SM22+, and Nox5+ mice, before and after Ang II treatment. C,
Representative images of Sirius Red staining of heart tissue from WT and SM22+Nox5+ mice, treated or not
with Ang II, exposed to polarized light microscopy. D, Total collagen deposition in heart tissue from WT and
SM22+Nox5+ mice, before and after Ang II treatment. E, Cardiomyocyte area in heart tissue from WT and
SM22+Nox5+ mice, before and after Ang II treatment. Results are meanSEM of 5 to 8 mice/group.
*P<0.05 vs control WT group; **P<0.05 vs nontreated counterpart. Ang II indicates angiotensin II; HPLC,
high-performance liquid chromatography; Nox5, NADPH Oxidase 5; WT, wild-type.
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Figure 3. Vascular contraction is increased in Nox5+/SM22+ mice. A, Vascular contractility to U46619
assessed by wire myography in mesenteric arteries from WT (open circle), SM22+ (open triangle), Nox5+
(open rhombus) and Nox5+/SM22+ (open square). B, Vascular contractility to U46619 in mesenteric
arteries from WT (open circle), WT+Ang II (closed circle), Nox5+/SM22+ (open square), and Nox5+/
SM22++Ang II (closed square) mice. C, Vascular contractility to U46619 in mesenteric arteries from WT
(open circle) and Nox5+/SM22+ (open square) mice in the presence of N-acetylcysteine (NAC; 10 lmol/L)
(WT, closed circle; Nox5+/SM22+, closed square). Vessels were pre-incubated with NAC for 1 hour. D,
Vascular contractility to U46619 in arteries from WT (open circle) and Nox5+/SM22+ (open square) mice in
the presence of GKT137831 (10 lmol/L; WT, closed circle; Nox5+/SM22+, closed square). Vessels were
preincubated with GKT137831 for 1 hour. E, Vascular contractility to U46619 in mesenteric arteries from
WT (open circle) and Nox5+/SM22+ (open square) mice in the presence of calmidazolium (Calmid; 1 lmol/
L; WT, closed circle; Nox5+/SM22+, closed square). Vessels were preincubated with calmidazolium for
1 hour. F, Vascular contractility to U46619 in arteries from WT (open circle) and Nox5+/SM22+ (open
square) mice in the presence of dantrolene (Dant; 10 lmol/L; WT, closed circle; Nox5+/SM22+, closed
square). Vessels were preincubated with dantrolene for 1 hour. Results are meanSEM of 3 to 8 mice/
group. *P<0.05 vs WT; **P<0.05 vs untreated WT or Nox5+/SM22+ (open symbols). Ang II indicates
angiotensin II; Nox5, NADPH Oxidase 5; WT, wild-type.
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which trigger actin-myosin cross-bridge formation. Ionomycin-
stimulated Ca2+ influx was significantly greater in Nox5+SM22+
VSMCs compared with WT cells (Figure 8A). These processes
wereassociatedwith increasedphosphorylationof the inhibitory
regulatory subunit of MLCP (myosin light chain phosphatase),
MYPT1 (Figure 8B through 8D). Phosphorylation of MLC20
(Thr18/Ser 19) was greater in Nox5+SM22+ VSMCs compared
with WT controls (Figure 8C and 8D).
Figure 4. Maximum contraction to KCl and ET-1–induced contraction are increased in arteries from
Nox5+/SM22+ mice. A, Vascular contraction to a single concentration of KCl (62.5 mmol/L) in mesenteric
arteries from WT, Nox5+/SM22+, SM22+, and Nox5+ mice, before and after treatment with Ang II. B,
Vascular contraction to KCl in mesenteric arteries from WT and Nox5+/SM22+ mice, before and after
preincubation (1 hour) with diltiazem (10 lmol/L) or calmidazolium (10 lmol/L). C, Vascular contraction
to KCl in mesenteric arteries from WT and Nox5+/SM22+ mice, before and after preincubation (1 hour) with
NAC (10 lmol/L) or GKT137831 (10 lmol/L). D, Vascular contraction to a single concentration of ET-1
(0.1 mmol/L) in mesenteric arteries from WT and Nox5+/SM22+ mice. Vascular contraction to ET-1 in
mesenteric arteries from WT and Nox5+/SM22+ mice, before and after preincubation (1 hour) with NAC
(10 lmol/L) or GKT137831 (10 lmol/L; E) or calmidazolium (10 lmol/L; F). Results are meanSEM of 3
to 8 mice/group. *P<0.05 vs WT; **P<0.05 vs untreated mice. Ang II indicates angiotensin II; ET-1,
endothelin-1; NAC, N-acetylcysteine; Nox5, NADPH Oxidase 5; WT, wild-type.
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Differential Expression of Vascular Nox Isoforms
in Nox5+SM22+ Mice
To evaluate whether human Nox5 influences expression of
endogenous Nox isoforms in vessels from Nox5+SM22+ mice,
we measured protein content of Nox1, Nox2, and Nox4 in
vascular tissue from WT and Nox5+SM22+ mice. As shown in
Figure S6, expression of Nox2 and Nox4 was not different
between WT and Nox5+SM22+ groups. However, expression
of Nox1 was increased in Nox5+SM22+ mice compared with
WT counterparts. In heart tissue, we did not observe any
differences in mRNA levels of Nox2 (Figure S7A) and Nox4
(Figure S7B), whereas mRNA levels of Nox1 were undected.
Decreased Gut Contraction in Nox5-Silenced R.
prolixus
To further examine the role of Nox5 in in intact system that
endogenously expresses functionally active Nox5, we studied
R. prolixus. As shown in Figure S8A, exposure of WT R.
prolixus to a feeding stimulus induced a significant increase in
Nox5 expression. Silencing of Nox5 with dsRNA resulted in a
significant reduction in frequency of midgut contraction
(peristalsis) following feeding, suggesting an important role
for Nox5 in gut muscle contraction (Figure S8B). VAS2870, a
Nox1/4 inhibitor, at low (0.02 mmol/L) and high (0.1 mmol/
L) concentrations, had no effect on feeding-stimulated
peristaltic contraction (Figure S8C).
Discussion
Since its discovery, the function of Nox5 and the significance
of its absolute dependency on intracellular Ca2+ for its
activation have been elusive. Here, we provide new insights
into the pathophysiological role of Nox5, identifying it as a
novel regulator of smooth muscle contraction important in
vascular function. Major findings from our study demonstrate
that: (1) transgenic mice expressing human Nox5 in VSMCs
exhibit systemic and vascular oxidative stress and vascular
hypercontractility, responses that are normalized by inhibitors
of Ca2+ channels, calmodulin, and ER ryanodine receptors;
Figure 5. Vascular expression of Nox5 induces endothelial dysfunction. A, Vascular relaxation to ACh
assessed by wire myography in mesenteric arteries from WT (open circle), SM22+ (open triangle), Nox5+
(open rhombus), and Nox5+SM22+ (open square). B, Vascular relaxation to ACh in arteries fromWT (open
circle), WT+Ang II (closed circle), Nox5+/SM22+ (open square), and Nox5+/SM22++Ang II (closed
square) mice. C, Vascular relaxation to ACh assessed by wire myography in mesenteric arteries from WT
(open circle), SM22+ (open triangle), and Nox5+ (open rhombus) before and after Ang II treatment (closed
symbols). Results are meanSEM of 5 to 8 mice/group. *P<0.05 vs WT; **P<0.05 vs untreated WT or
Nox5+/SM22+ (open symbols). ACh indicates acetylcholine; Ang II, angiotensin II; Nox5, NADPH Oxidase
5; WT, wild-type.
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(2) vascular expression of Nox5 is associated with cardiac
oxidative stress and fibrosis; and (3) Nox5 does not influence
Ang II pressor responses. These data define Nox5 as a pro-
contractile Nox isoform that regulates vascular contraction
through molecular processes involving ROS, Ca2+, calmodulin,
and the ER. In support of our findings, we demonstrated that
muscle contraction in an invertebrate model that expresses
Nox5 endogenously is attenuated when Nox5 is silenced, but
not when Nox1 and Nox4 are inhibited. Together, our studies
identify a novel function for Ca2+-sensitive Nox5 in redox
regulation of smooth muscle contraction, processes that may
have significant implications in vascular (patho)physiology.
Noxs are increasingly being recognized as key sources of
ROS in vascular cells, with specific Nox isoforms regulating
distinct signaling pathways. For example, whereas Nox1- and
Nox2-derived O2 regulate proinflammatory and mitogenic
signaling pathways,37,38 Nox4 generates mainly H2O2, an
endothelium-derived hyperpolarizing factor that controls
vasodilation.39 The importance of NADPH oxidase-derived
ROS in the regulation of vascular tone was demonstrated in
patients with hereditary deficiency of Nox2, who exhibit
increased flow-mediated vasodilation.40 Despite advances in
Nox research, progress in Nox5 biology, especially in the
cardiovascular system, in in vivo settings, has been slow
because of lack of research tools and experimental models.
Nox5 was originally identified in testis, ovaries, spleen, and
immature lymphocytes and is heavily expressed in various
cancers.17 More recently, Nox5 has been demonstrated in the
vascular system. In bovine aortic endothelial cells, Nox5 is
required for stromal cell–derived factor-1a andMAPK (mitogen-
activated protein kinase) signaling, which regulate endothelial
migration and angiogenesis.41 In human endothelial cells, Ang
II– and ET-1–induced redox signaling and MAPK activation are
Nox5 dependent.25 In adenovirus-mediated Nox5 overexpres-
sion in endothelial cells, phosphorylation of p38 MAPK, JAK2
(Janus kinase 2), JNK (c-Jun N-terminal kinase), and ERK1/2
(extracellular signal-regulated kinases 1 and 2) was increased,12
whereas in VSMCs, Nox5 only increased ERK1/2 phosphory-
lation.
To investigate the pathophysiological significance of vas-
cular smooth muscle Nox5 in vivo, we generated mice
expressing human Nox5 exclusively in smooth muscle cells.
Figure 6. Cross-sectional area (CSA) in resistance arteries from Nox5+/SM22+ mice. A, Vascular
CSA assessed by pressure myography in mesenteric arteries from WT (open circle), SM22+ (open
triangle), Nox5+ (open rhombus), and Nox5+/SM22+ (open square). B, Vascular CSA assessed by
pressure myography in mesenteric arteries from SM22+ (open triangle) and Nox5+ (open rhombus),
before and after Ang II treatment (closed symbols). C, Vascular CSA assessed by pressure myography
in mesenteric arteries from WT (open circle) and Nox5+/SM22+ (open square), before and after Ang II
treatment (closed symbols). Results are meanSEM of 5 to 8 animals per group. *P<0.05 vs
untreated groups. Ang II indicates angiotensin II; Nox5, NADPH Oxidase 5; WT, wild-type.
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These mice exhibited significant oxidative stress, both
systemically and in the vasculature and heart, indicating the
functional activation of ROS-generating Nox5 in our model.
Although these mice had normal blood pressure, they
exhibited significant changes in vascular function as well as
some evidence of cardiac changes, particularly fibrosis and
cardiomyocyte hypertrophy, suggesting that Nox5-induced
ROS generation in the vasculature impacts cardiac cells,
possibly through redox-sensitive signaling pathways. The
most marked phenotype in the Nox5 mice was vascular
Figure 7. ROS production in arteries and VSMCs from Nox5+SM22+ mice. A, Nitrotyrosine levels, a marker
of ONOO, in aorta from WT and Nox5+/SM22+ mice measured by ELISA. B, ROS generation in VSMCs from
WT and Nox5+SM22+ mice assessed by lucigenin chemiluminescence. Relative luminescence units (RLU)
were corrected by protein concentration of each sample. C, Basal ROS production in VSMCs from mesenteric
arteries from Nox5+SM22+ mice after incubation with verapamil (10 lmol/L), calmidazolium (1 lmol/L),
and dantrolene (10 lmol/L). D, U46619-stimulated ROS generation in VSMCs from mesenteric arteries from
WT and Nox5+SM22+ mice. U46619-induced ROS production in VSMCs from mesenteric arteries from WT (E)
and Nox5+SM22+ (F) after preincubation with verapamil and dantrolene. Results are meanSEM of 3 to 6
experiments. *P<0.05 vs control WT; **P<0.05 vs control nonstimulated WT or Nox5+SM22+. W in (F)
represents basal ROS generation in WT VSMCs. Nox5 indicates NADPH Oxidase 5; ONOO, peroxynitrite;
ROS, reactive oxygen species; VSMCs, vascular smooth muscle cells; WT, wild-type.
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hypercontractility, which was not exacerbated by Ang II.
Potential mechanisms associated with Nox5-induced vascular
changes involve ROS, Ca2+, and calmodulin, because vascular
hyper-reactivity was normalized by N-acetylcysteine, Ca2+
channel blockers, and calmidozilium. These findings are in line
with the fact that Nox5-derived ROS production is dependent
on [Ca2+]i and calmodulin.
42 We also showed that ER Ca2+
mobilization may be important because dantrolene, which
blocks ryanodine receptor, reduced contraction only in Nox5
mice. Previous studies in coronary arterial myocytes and
pulmonary arterial smooth muscle cells demonstrated that
ryanodine receptor/Ca2+ regulation involves ER-associated
Nox (2 and 4)-derived ROS.43,44 Our findings are supportive of
this association, although the exact role of Nox5 in ER
function warrants further investigation.
Nox isoforms may regulate one another, either through
redox-dependent processes that influence transcription fac-
tors and gene expression or directly through protein-protein
interactions.45,46 In our study, Nox5 did not influence Nox2 or
Nox4 expression, in the vasculature or heart, but it was
Figure 8. Molecular mechanisms of vascular dysfunction in Nox5+SM22+ mice. A, Ca2+ influx induced by
ionomycin in VSMCs from WT and Nox5+/SM22+ mice measured by live cell microscopy using the
fluorescent probe, CAL520-AM. B, Representative immunoblotting images of phosphorylation of MYPT1 and
MLC20, corrected to total GAPDH expression. C, MYPT1 phosphorylation in VSMCs from WT and Nox5+/
SM22+ mice. D, MLC20 phosphorylation in VSMCs from WT and Nox5+/SM22+ mice. Results are
meanSEM of 3 to 5 experiments. *P<0.05 vs WT. GAPDH indicates glyceraldehyde 3-phosphate
dehydrogenase; MLC20, myosin light chain 20; MYPT1, myosin phosphatase target subunit 1; Nox5, NADPH
Oxidase 5; VSMCs, vascular smooth muscle cells; WT, wild-type.
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associated with an increase in vascular Nox1 content.
Reasons for this remain unclear. However, Nox1 upregulation
did not seem to significantly influence vascular hypercontrac-
tility in Nox5 mice because GKT137831 did not inhibit
exaggerated contractile responses in Nox5-expressing mice.
Molecular processes underlying Nox5-induced vascular
dysfunction were further interrogated in VSMCs cultured from
WT and Nox5 mice. In Nox5-expressing cells, oxidative stress,
[Ca2+]i and pro-contractile signaling pathways were increased.
In particular, phosphorylation of MYPT1 at Thr-696 and
phosphorylation of MLC20 at Thr18/Ser19 were increased in
VSMCs from Nox5 mice. Phosphorylation of MYPT1 causes
inhibition of myosin phosphatase, which leads to increased
Ca2+ sensitization and increased force of vascular smooth
muscle contraction.47 Hence, the increased phosphorylation
of MYPTI and MLC20 in the Nox5-expressing mice may be
indicative of increased pro-contractile signaling, which is in
line with our other vascular findings.
In addition to increased contraction, Nox5-expressing mice
exhibited impaired endothelium-dependent vasorelaxation,
processes that were associated with reduced phosphorylation
of endothelial nitric oxide synthase and increased vascular
ONOO content. Given that Nox5 was expressed exclusively
in vascular smoothmuscle in ourmousemodel, it is unlikely that
the endothelial changes are directly attributed to Nox5. How-
ever, there may be important cross-talk between the endothe-
lium and vascular media through Nox5-derived ROS, where
vascular oxidative stress in Nox5micemay promote endothelial
nitric oxide synthase uncoupling, decreased endothelial nitric
oxide synthase activation with reduced nitric oxide generation,
increased superoxide production, and consequent ONOO
formation, processes that cause endothelial dysfunction.48
In Ang II–infused WT mice, contractile responses were
increased and endothelium-dependent vasorelaxation was
impaired. These effects were not further aggravated by Nox5.
Reasons for this are unclear, but may relate, at least in part, to
the fact that in Nox5 mice vessels are already hypercontrac-
tile with endothelial dysfunction in the basal state before Ang
II treatment and that further responses may be blunted.
Despite the critical role of Nox5 in the regulation of
vascular function, it seemed to be less important in processes
that control vascular structure and mechanics, given that
vascular wall thickness, stiffness, and distensibility were not
influenced by Nox5 in basal conditions, despite increased
oxidative stress. When challenged with Ang II, arteries from
WT mice exhibited significant remodeling as evidenced by an
increase in cross-sectional area. In Ang II–infused Nox5 mice,
remodeling was less marked than WT counterparts. Preser-
vation of vascular structure and mechanical integrity, and
modest remodeling induced by Ang II, may explain, at least in
part, why Nox5 did not significantly influence blood pressure
in basal or Ang II–stimulated conditions.
During evolution, for unknown reasons, the Nox5 gene was
lost in rodents, but is present and functionally active in some
invertebrates and in higher mammals.17 Arthropods possess
Nox5, an ortholog of human Nox5, besides dual oxidase, and
some of them also possess Nox4-art, a gene related to
Nox4.31,49 As such, we further examined the relationship
between Nox5 and contraction by studying R. prolixus where
midgut contraction is easily studied by videomicroscopy.
Feeding induced a significant increase in Nox5 expression in
R. prolixus, with associated increase in midgut contraction.
However, in Nox5-silenced R. prolixus, feeding-stimulated
contractile responses were markedly blunted, highlighting the
importance of Nox5 in the regulation of muscle contraction.
This was confirmed in our studies with VAS2870, a NOX1/4
inhibitor that had no effect on feeding-stimulated peristaltic
contractions. The biological importance of Nox5 in smooth
muscle contraction was also shown in Drosophila melanoga-
ster, where depletion of Nox5 (dNox) in the musculature was
studied using RNA interference approaches.50 dNox-RNAi
Drosophila exhibited retention of mature eggs, impaired
ovarian muscle contractions, and sterility attributed to altered
agonist-induced calcium flux and decreased muscle contrac-
tion. The muscles that control Rhodnius gut and Drosophila
ovarian muscles are typical of smooth muscle and derive from
mesoderm, similar to that in mammals, and hence biological
processes controlling contraction may be similar between
species. Together these findings strongly support the notion
that Nox5 is a pro-contractile NADPH oxidase isoform, an
ancestral role that is conserved during animal evolution.
In conclusion, using a multidisciplinary approach, including
Nox5 transgenic mice, cultured VSMCs from Nox5 mice, and
Nox5-expressing arthropod models, we define an important
role for Nox5 in the regulation of smooth muscle contraction
and vascular function. Nox5 may be a key nexus linking Ca2+
and ROS to the pro-contractile molecular machinery in
VSMCs. Upregulation of the Ca2+-regulated Nox5-ROS-Ca2+
pathway may be especially important in cardiovascular
diseases associated with vascular hypercontractility, such as
coronary artery disease, vasospastic conditions, hypertension,
and cerebral vasospasm.
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